| GVIRF 2025 Detailed Agenda | GVIRF Secretariat | 2025 | Webinar | Anglais |
| GVIRF 2025 Call for Abstracts | | 2024 | Poster/infographic | Anglais |
| P1-1 Innovations in vaccine discovery | Galit Alter | 2025 | Presentation | Anglais |
| P1-2 Innovation in vaccine development | Andrew Pollard | 2025 | Presentation | Anglais |
| P1-3 Delivering vaccines: Vaccine innovation ecosystem past, present, and future | Anne Schuchat | 2025 | Presentation | Anglais |
| P1-4 Vaccination overview in Brazil | Eder Gatti | 2025 | Presentation | Anglais |
| P2-1 Pathogen prioritization at the global level: WHO Global Priority Endemic Pathogens for Vaccine R&D | Mateusz Hasso-Agopsowicz | 2025 | Presentation | Anglais |
| P2-2 Prioritizing pathogens with epidemic and pandemic potential | Jakob Cramer | 2025 | Presentation | Anglais |
| P2-3 Setting R&D Priorities – Bio-Manguinhos’ Perspectives | Ricardo de Godoi | 2025 | Presentation | Anglais |
| P2-4 Development of vaccines for global use: Role of the vaccine industry | Luis Jodar | 2025 | Presentation | Anglais |
| P3-1 The Value of Health R&D –The Return on Investment | Nick Chapman | 2025 | Presentation | Anglais |
| P3-2 The infectious diseases vaccines R&D financing landscape: An Industrial perspective | Nick Jackson | 2025 | Presentation | Anglais |
| P3-3 The CEPI R&D Funding Model | Aurélia Nguyen | 2025 | Presentation | Anglais |
| P4-1 Introduction: Why is innovation in clinical trials needed now? | Peter Dull | 2025 | Presentation | Anglais |
| P4-2 Clinical immunobridging strategy to support licensure of preventive vaccines | Marion Gruber | 2025 | Presentation | Anglais |
| P4-3 A systematic approach to identification of correlates of protection | Deborah King | 2025 | Presentation | Anglais |
| P4-4 Vaccine efficacy evidence generation in outbreaks | Jakob Cramer | 2025 | Presentation | Anglais |
| P5-1 Overview of arbovirus vaccines | Melanie Saville | 2025 | Presentation | Anglais |
| P5-2 What is the current state of dengue vaccine development and new technologies? | Esper Kallas | 2025 | Presentation | Anglais |
| P5-3 Approved Chikungunya vaccines | Marco Cavaleri | 2025 | Presentation | Anglais |
| P5-4 Yellow Fever Vaccination: Fractional dosing and one versus two life-time doses | Patricia Mouta Nunes de Oliveira | 2025 | Presentation | Anglais |
| P6-1 What have we learned in the COVID19 pandemic? | Ricardo Tostes Gazzinelli | 2025 | Presentation | Anglais |
| P6-2 Global and Regional Vaccine R&D Update | Maria Elena Bottazzi | 2025 | Presentation | Anglais |
| P6-3 mRNA vaccine production capacity building in Latin America | Tomás Pippo | 2025 | Presentation | Anglais |
| P6-4 Case studies for clinical trial capacity in the region | Sue Ann Costa Clemens | 2025 | Presentation | Anglais |
| P7-1 Predicting infectious disease responses to climate change | Sonia Altizer | 2025 | Presentation | Anglais |
| P7-2 Oceans, climate and health: The cholera paradigm | Rita Colwell | 2025 | Presentation | Anglais |
| P7-3 Climate change and vaccine-preventable diseases | Neil Ferguson | 2025 | Presentation | Anglais |
| P8-1 Equitable and sustainable access to new vaccines: Where are we and what will it take? | Tara Prasad | 2025 | Presentation | Anglais |
| P8-2 Regional Revolving Funds | Santiago Cornejo | 2025 | Presentation | Anglais |
| W1-1 Trends in vaccine technology innovations | Jorge Kalil | 2025 | Presentation | Anglais |
| W1-2 Novel adjuvants and mucosal vaccination strategies | Ed Lavelle | 2025 | Presentation | Anglais |
| W1-3 Oral delivery of biologics | Giovanni Traverso | 2025 | Presentation | Anglais |
| W1-4 Glycoconjugate Vaccines: Molecular architecture and controlled heterogeneity | John Hennessey | 2025 | Presentation | Anglais |
| W1-5 Novel Vaccines Technologies: Moving to the Clinic | Hana El Sahly | 2025 | Presentation | Anglais |
| W2-1 AMR burden and prevalence: Global perspective and a vision from Latin America | Carlos Kiffer | 2025 | Presentation | Anglais |
| W2-2 Scientific evidence demonstrating the impact of vaccines on Antimicrobial Resistance | Mateusz Hasso-Agopsowicz | 2025 | Presentation | Anglais |
| W2-3 Vaccine development against AMR priority pathogens: Staphylococcus aureus, Klebsiella pneumoniae and extraintestinal pathogenic Escherichia coli | Rino Rappuoli | 2025 | Presentation | Anglais |
| W3-1 What is implementation research and why should it be mainstreamed into immunization systems in the African Region? | Abdu Adamu | 2025 | Presentation | Anglais |
| W3-2 Economic evidence generation through field-based implementation research | Jung-Seok Lee | 2025 | Presentation | Anglais |
| W3-3 How has implementation evidence informed Indonesia’s vaccine introduction policies? Lessons learned from the CAPACITI decision-support tool | Auliya Suwantika | 2025 | Presentation | Anglais |
| W3-4 The current experience of conducting implementation research to inform malaria vaccine roll-out | Kwaku Poku Asante | 2025 | Presentation | Anglais |
| W4-1 Accelerating the development of new tuberculosis (TB) vaccines for adults and adolescents | Willem Hanekom | 2025 | Presentation | Anglais |
| W4-2 Challenges and Opportunities in TB Vaccine Development | Ann Ginsberg | 2025 | Presentation | Anglais |
| W4-3 Feasibility and potential consequences of including asymptomatic TB in the primary endpoint in vaccine licensure trials | Richard White | 2025 | Presentation | Anglais |
| W4-4 The considerations of including people deprived of liberty (PDL) in TB vaccine licensure trials | Julio Croda | 2025 | Presentation | Anglais |
| W5-1 Passive immunization in preventing disease: Overview, rationale, and common challenges | Erin Sparrow | 2025 | Presentation | Anglais |
| W5-2 Evaluating impact of interventions for group B streptococcus and respiratory syncytial virus in infants | Anne Schuchat | 2025 | Presentation | Anglais |
| W5-3 Approaches to support maternal vaccine licensure and adoption | Annaliesa Anderson | 2025 | Presentation | Anglais |
| W5-4 Implementation and vaccine effectiveness studies of the RSV vaccine in Argentina | Santiago Olszevicki | 2025 | Presentation | Anglais |
